VKTX Viking Therapeutics, Inc.

Overview and Growth

In fiscal 2025, Viking Therapeutics, Inc. recorded $0.00 of revenue, net loss of $359.64M, and an operating cash outflow of $278.69M. The company reported diluted EPS of -$3.19, adding a shareholder-level measure to the absolute income figures considered below. Diluted shares averaged 112.67M; this is the reported share base over which the company’s diluted per-share earnings were spread. The diluted share count was 3.3% higher than fiscal 2024, when diluted shares averaged 109.04M, adding context to the EPS comparison. Total assets stood at $715.73M, showing the scale of resources supporting revenue, earnings, liquidity, and financing.

Profitability

The company recorded an operating loss of $393.34M after the reported operating expense base. The company ended the period with a net loss of $359.64M, extending the operating result through all remaining items. The pretax result was a loss of $359.64M, establishing the deficit before tax effects. The reported income-tax provision was $1.00K, the amount recognized between pretax income and the final net-income result. The net loss equaled 56.3% of period-end equity, showing the deficit relative to book capital. Relative to total assets, the net loss represented 50.2%. The bottom-line deficit increased from $109.96M in fiscal 2024 to $359.64M.

Liquidity and Capital Structure

Total assets were $715.73M, supported by $76.67M of liabilities and $639.06M of shareholder equity. Current assets were $715.60M against $76.67M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. The current ratio was 9.33x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Cash and equivalents totaled $165.81M, identifying the most liquid reported component available within the broader current-asset balance. Cash and equivalents represented 216.3% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Equity equaled 89.3% of assets, showing the shareholder-capital layer within the company’s balance sheet. The liabilities-to-assets relationship was 10.7%, placing reported obligations against the full positive asset balance. Cash and equivalents equaled 23.2% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 21.2% from $908.32M in fiscal 2024, leaving current total assets lower year over year. Against $880.28M of equity in fiscal 2024, the current book-equity balance moved 27.4% and ended lower. Compared with $26.68M in fiscal 2024, the current cash balance moved 521.6% and finished higher.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $278.69M, showing that operations absorbed cash during the period. Compared with a $87.79M operating cash outflow in fiscal 2024, the current outflow increased to $278.69M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.